Certain embodiments of the invention include recombinant reverse genetic systems for SARS-COV-2 virus.

Disclosed herein is a protein-based, genetically-encoded bioluminescent sensor that can report changes in intracellular ATP in live cells. This sensor is built from the NanoLuc luciferase (Promega) and mScarlet red fluorescent protein (DOI: 10.1038/nmeth.4074) in a novel platform that provides a much more quantitative optical signal for measurements. Analytical Chemistry demonstrates its characterization and that it can be used to image ATP differences in live cells under the skin of mice. This new sensor can be very useful for research purposes in cancer biology to measure cell health and chemotherapeutic drug efficacy for example in animal models of tumors or in cell-based screening.

Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.

Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.

Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.

A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.

Bioluminescent biosensors useful for monitoring and/or quantifying, in vitro or in vivo, activity of the Hippo signaling pathway. The biosensors monitor LATS kinase activity or YAP-TEAD interaction. The biosensors may be used in methods for monitoring and/or quantifying in real-time, in vitro or in vivo, activity of the Hippo signaling pathway, wherein the activity may be LATS kinase activity and/or YAP-TEAD interaction. The biosensors may be provided in kits for monitoring and/or quantifying in real-time, in vitro or in vivo, activity of the Hippo signaling pathway, wherein the activity may be LATS kinase activity and/or YAP-TEAD interaction.

A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.

Provided herein are systems, methods, and compositions for bioluminescence-triggered catalysis of bioorthogonal labeling chemistries in a proximity dependent manner. In particular, provided herein are bioluminescent proteins or complexes, luminophore substrates thereof, photocatalysts or photosensitizers, activatable labels, and systems thereof, and methods of catalytically activating the activatable labels via bioluminescence-triggered catalysis.

The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a GC content of not less than 60% is achieved. A gene design method which involves the feature only preferential codons with high frequency of use are selected and a GC content of not less than 60% is achieved can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes.